Novo's Weight-Loss Drug Wegovy Helps with Fatty Liver

Novo Nordisk recently announced that its weight-loss drug, semaglutide, showed promising results in a late-stage trial for treating a type of fatty liver disease called MASH (metabolic dysfunction-associated steatohepatitis). This condition, which affects around 5% of U.S. adults, causes inflammation and scarring in the liver due to fat buildup, with limited treatment options currently available.

The trial tested a 2.4 mg dose of semaglutide, already marketed as Wegovy for weight loss and Ozempic for diabetes, in 800 patients. After 72 weeks, 37% of those on the drug showed liver scarring improvement without further liver damage, compared to 22.5% on placebo. Additionally, 62.9% of patients on semaglutide experienced resolution of liver inflammation, in contrast to 34.1% on placebo.

Novo Nordisk’s findings come as rival Madrigal Pharmaceuticals has also made strides in this space, with its drug Rezdiffra. Analysts believe Novo’s semaglutide could potentially expand treatment options for MASH and increase sales outside its current obesity market. Following these results, Novo Nordisk’s shares rose by 1% in Copenhagen, while Madrigal's shares jumped 22%.

Novo Nordisk plans to seek regulatory approval for MASH treatment in the U.S. and EU by mid-2025. The company, along with competitor Lilly, is exploring semaglutide and tirzepatide (found in Mounjaro) for other health conditions, including Alzheimer’s disease, pointing to an expanding market for these medications beyond weight loss.

If you're interested to buy Wegovy online, Farmeci offers a convenient and reliable option! We provide a free prescription if you’re a suitable candidate, helping you safely start this effective medication.